Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use
Live-attenuated Rift Valley fever (RVF) vaccines transiently replicate in the vaccinated host, thereby effectively initiating an innate and adaptive immune response. Rift Valley fever virus (RVFV)-specific neutralizing antibodies are considered the main correlate of protection. Vaccination with clas...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/11/3/707 |
_version_ | 1827747330029256704 |
---|---|
author | Paul J. Wichgers Schreur Brian H. Bird Tetsuro Ikegami Erick Bermúdez-Méndez Jeroen Kortekaas |
author_facet | Paul J. Wichgers Schreur Brian H. Bird Tetsuro Ikegami Erick Bermúdez-Méndez Jeroen Kortekaas |
author_sort | Paul J. Wichgers Schreur |
collection | DOAJ |
description | Live-attenuated Rift Valley fever (RVF) vaccines transiently replicate in the vaccinated host, thereby effectively initiating an innate and adaptive immune response. Rift Valley fever virus (RVFV)-specific neutralizing antibodies are considered the main correlate of protection. Vaccination with classical live-attenuated RVF vaccines during gestation in livestock has been associated with fetal malformations, stillbirths, and fetal demise. Facilitated by an increased understanding of the RVFV infection and replication cycle and availability of reverse genetics systems, novel rationally-designed live-attenuated candidate RVF vaccines with improved safety profiles have been developed. Several of these experimental vaccines are currently advancing beyond the proof-of-concept phase and are being evaluated for application in both animals and humans. We here provide perspectives on some of these next-generation live-attenuated RVF vaccines and highlight the opportunities and challenges of these approaches to improve global health. |
first_indexed | 2024-03-11T05:46:58Z |
format | Article |
id | doaj.art-42f86dbf9288445b8cc1eafc71499e44 |
institution | Directory Open Access Journal |
issn | 2076-393X |
language | English |
last_indexed | 2024-03-11T05:46:58Z |
publishDate | 2023-03-01 |
publisher | MDPI AG |
record_format | Article |
series | Vaccines |
spelling | doaj.art-42f86dbf9288445b8cc1eafc71499e442023-11-17T14:19:52ZengMDPI AGVaccines2076-393X2023-03-0111370710.3390/vaccines11030707Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human UsePaul J. Wichgers Schreur0Brian H. Bird1Tetsuro Ikegami2Erick Bermúdez-Méndez3Jeroen Kortekaas4Department of Virology and Molecular Biology, Wageningen Bioveterinary Research, Wageningen University & Research, 8221 RA Lelystad, The NetherlandsOne Health Institute, School of Veterinary Medicine, University of California, Davis, CA 95616, USADepartment of Pathology, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USADepartment of Virology and Molecular Biology, Wageningen Bioveterinary Research, Wageningen University & Research, 8221 RA Lelystad, The NetherlandsDepartment of Virology and Molecular Biology, Wageningen Bioveterinary Research, Wageningen University & Research, 8221 RA Lelystad, The NetherlandsLive-attenuated Rift Valley fever (RVF) vaccines transiently replicate in the vaccinated host, thereby effectively initiating an innate and adaptive immune response. Rift Valley fever virus (RVFV)-specific neutralizing antibodies are considered the main correlate of protection. Vaccination with classical live-attenuated RVF vaccines during gestation in livestock has been associated with fetal malformations, stillbirths, and fetal demise. Facilitated by an increased understanding of the RVFV infection and replication cycle and availability of reverse genetics systems, novel rationally-designed live-attenuated candidate RVF vaccines with improved safety profiles have been developed. Several of these experimental vaccines are currently advancing beyond the proof-of-concept phase and are being evaluated for application in both animals and humans. We here provide perspectives on some of these next-generation live-attenuated RVF vaccines and highlight the opportunities and challenges of these approaches to improve global health.https://www.mdpi.com/2076-393X/11/3/707live-attenuatedvaccinereverse geneticsRift Valley fever virusnext-generation |
spellingShingle | Paul J. Wichgers Schreur Brian H. Bird Tetsuro Ikegami Erick Bermúdez-Méndez Jeroen Kortekaas Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use Vaccines live-attenuated vaccine reverse genetics Rift Valley fever virus next-generation |
title | Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use |
title_full | Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use |
title_fullStr | Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use |
title_full_unstemmed | Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use |
title_short | Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use |
title_sort | perspectives of next generation live attenuated rift valley fever vaccines for animal and human use |
topic | live-attenuated vaccine reverse genetics Rift Valley fever virus next-generation |
url | https://www.mdpi.com/2076-393X/11/3/707 |
work_keys_str_mv | AT pauljwichgersschreur perspectivesofnextgenerationliveattenuatedriftvalleyfevervaccinesforanimalandhumanuse AT brianhbird perspectivesofnextgenerationliveattenuatedriftvalleyfevervaccinesforanimalandhumanuse AT tetsuroikegami perspectivesofnextgenerationliveattenuatedriftvalleyfevervaccinesforanimalandhumanuse AT erickbermudezmendez perspectivesofnextgenerationliveattenuatedriftvalleyfevervaccinesforanimalandhumanuse AT jeroenkortekaas perspectivesofnextgenerationliveattenuatedriftvalleyfevervaccinesforanimalandhumanuse |